valsartan has been researched along with Benign Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 14 (73.68) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Li, T; Wang, L; Xi, Q | 1 |
| Chan, TH; Tsoi, MF; Yung Cheung, BM | 1 |
| Biondi-Zoccai, G; Bocchi, EA; Chan, JS; de Souza Lima Bitar, Y; Duraes, AR; Liu, T; Mesquita, ET; Neto, MG; Roever, L; Tse, G | 1 |
| Jones, AM; Salim, H | 1 |
| Gok, M; Ozturk, C; Yalta, K; Yalta, T | 1 |
| Lewicka, E; Sławiński, G | 1 |
| Jeon, HL; Lee, SH; Nam, JH; Shin, JY | 1 |
| Hu, WS; Lin, CL | 1 |
| Tchernev, G | 1 |
| Díaz-Peláez, E; Ibáñez, B; Martín-García, A; Martín-García, AC; Sánchez, PL; Sánchez-González, J | 1 |
| Castro, A; Chaparro-Muñoz, M; López-Fernández, T; Lopez-Sendon, JL; Martín-Garcia, A; Martin-Garcia, AC; Martinez-Monzonis, A; Mitroi, C; Moliner, P; Sanchez, PL | 1 |
| Liu, T; Roever, L; Tse, G; Wang, Y | 1 |
| Broich, K; Brückner, G; Frötschl, R; Gomm, W; Haenisch, B; Heß, S; Röthlein, C; Schröder, H; Schüssel, K | 1 |
| Banzi, R; Bertele', V | 1 |
| Ernst, MT; Hallas, J; Johansen, NB; Kristensen, KB; Pottegård, A; Quartarolo, P | 1 |
| Bosch, FH; Jilesen, DPMW; Kerkvliet, CTM; Kramers, C | 1 |
| Al-Kindi, SG; Oliveira, GH | 1 |
| Lee, T | 1 |
1 review(s) available for valsartan and Benign Neoplasms
| Article | Year |
|---|---|
Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction: a systematic review of clinical and preclinical studies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Neoplasms; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2022 |
18 other study(ies) available for valsartan and Benign Neoplasms
| Article | Year |
|---|---|
Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2022 |
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Neoplasms; Tetrazoles; Valine; Valsartan | 2022 |
Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug-Related Side Effects and Adverse Reactions; Excipients; Humans; Neoplasms; Retrospective Studies; Valsartan | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? Authors' reply.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Cancer risk associated with the use of valsartan in Korea: A nationwide cohort study.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Studies; Humans; Neoplasms; Retrospective Studies; Valsartan | 2022 |
Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk.
Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neoplasms; Risk; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2023 |
NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CA
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Calcium Channel Blockers; Carcinogens; Humans; Keratoacanthoma; Neoplasms; Nifedipine; Nitrosamines; Propafenone; Shoulder; Surgical Flaps; Valsartan | 2023 |
Myocardial function and structure improvement with sacubitril/valsartan in cancer therapy-induced cardiomyopathy.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Humans; Male; Myocardial Contraction; Neoplasms; Stroke Volume; Tetrazoles; Valsartan | 2020 |
Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left | 2020 |
Sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neoplasms; Tetrazoles; Valsartan | 2020 |
N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer—A Longitudinal Cohort Study Based on German Health Insurance Data.
Topics: Cohort Studies; Dimethylnitrosamine; Drug Contamination; Humans; Neoplasms; Valsartan | 2021 |
Cancer risk from nitrosamine-contaminated valsartan.
Topics: Drug Contamination; Humans; Longitudinal Studies; Neoplasms; Nitrosamines; Valsartan | 2021 |
Regulatory response to contaminated valsartan.
Topics: Cohort Studies; Dimethylnitrosamine; Humans; Neoplasms; Tetrazoles; Valsartan | 2018 |
Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Colorectal Neoplasms; Denmark; Dimethylnitrosamine; Drug Contamination; Female; Humans; Male; Middle Aged; Neoplasms; Risk Factors; Uterine Neoplasms; Valsartan | 2018 |
[Valsartan contamination].
Topics: Antihypertensive Agents; Carcinogens; Dimethylnitrosamine; Drug Contamination; Drugs, Generic; Humans; Neoplasms; Valsartan | 2019 |
Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall.
Topics: Adverse Drug Reaction Reporting Systems; Angiotensin II Type 1 Receptor Blockers; Carcinogens; Diethylnitrosamine; Drug Contamination; Drug Recalls; Humans; Neoplasms; Patient Safety; Risk Assessment; Risk Factors; Time Factors; Valsartan | 2019 |
Ask the doctor. I read that angiotensin-receptor blockers cause cancer. I take one (Diovan) for my blood pressure. Should I stop?
Topics: Angiotensin II Type 1 Receptor Blockers; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Risk Assessment; Tetrazoles; Valine; Valsartan | 2010 |